Quidel Corp.

NASDAQ:QDEL   3:06:45 PM EDT
181.40
+6.96 (+3.99%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)7.71B
Current PE20.80
Forward PE 10.17
2yr Forward PE 4.76
See more stats
Estimates Current Quarter
Revenue$808.89 Million
Adjusted EPS$9.84
See more estimates
10-Day MA$191.95
50-Day MA$230.70
200-Day MA$182.43
See more pivots

QUIDEL CORP /DE/ Stock, NASDAQ:QDEL

12544 HIGH BLUFF DRIVE, SUITE 200, SAN DIEGO, CA 92130
United States of America
Phone: 8585521100
Number of Employees: 1224

Description

Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications primarily in infectious diseases, POC women's and general health, and gastrointestinal diseases. The company offers Sofia influenza A+B and QuickVue influenza tests to detect viral antigens of influenza type A and B; Sofia strep A fluorescent immunoassay and QuickVue Strep A tests to detect group A Streptococcal antigen from throat swabs; and Sofia Respiratory Syncytial Virus (RSV), QuickVue RSV, and Quidel Molecular RSV + human metapneumovirus tests for respiratory syncytial virus. It also provides various products to detect various herpes simplex virus (HSV) and herpes family viruses; H&V-Mix to isolate HSV, VZV, and Cytomegalovirus; R-Mix to detect Influenza A and B, RSV, Adenovirus, and Parainfluenza types 1, 2, and 3; Sofia S. Pneomoniae fluorescent immunoassay (FIA) to detect pneumococcal pneumonia and meningitis; Sofia Legionella FIA to detect Legionella pneumophila seorgroup 1 antigen; AmpliVue Bordetella assay to detect Bordetella pertussis; and Lyra Adenovirus assay to detect human adenovirus viral DNA. In addition, the company offers Sofia hCG fluorescent immunoassay and QuickVue pregnancy tests to detect hCG in serum or urine; Thyretain for the diagnosis of graves disease; QuickVue Chlamydia test to detect Chlamydia trachomatis; Solana Trichomonas assay for the diagnosis of trichomoniasis; and clinical and research products for the assessment of osteoporosis and evaluation of bone resorption/formation. Further, it provides Lyra Direct C. difficile assay to detect Clostridium difficile Toxin A or Toxin B genes; Super E-Mix and D3 IFA Enterovirus indirect fluorescent antibody products; QuickVue fecal immunochemical test to detect the presence of blood in stool specimens; and serological tests to measure antibodies circulating in the blood. Quidel Corporation was founded in 1979 and is headquartered in San Diego, California.